Agilent updates Visiopharm image analysis software

2019 12 12 00 55 0189 Breast Cancer3 400

Agilent Technologies has released an updated version of its Visiopharm image analysis software. The software now incorporates HercepTest monoclonal antibody (mAb) pharmDx for Dako Omnis.

The upgrade will allow pathologists to use Visiopharm HER2 App for breast cancer treatment decision support as they assess HercepTest mAb pharmDx slides.

HercepTest mAb pharmDx is used for breast cancer patients who are under consideration for Herceptin treatment; if HER2 is overexpressed, the patient may be a candidate, Agilent said.

Page 1 of 12
Next Page